TriPharm Services has announced its plans to develop a new pharmaceutical manufacturing centre in Morrisville, North Carolina, US.
The facility, utilising the latest isolator manufacturing equipment, will be situated at 627 Davis Drive, Morrisville and will cover an area of 32,000 square feet.
It will include four isolator filling suites with the highest level of control for Grade a processing and lyophilised formulations.
The facility will be specialised in manufacturing injectable pharmaceutical products including liquid and lyophilised parenteral products.
Additionally, it will also feature eight Grade C and D multi-purpose classrooms, along with advanced utilities for liquid parenteral formulations and equipment storage.
It will also have ten air handling units that provide separation for the production activities across every filling suite.
The facility will feature a full range of GMP storage conditions including walk-ins and reach-in chambers with generators and UPS systems, to ensure that critical operations are maintained during power outages.
The manufacturing centre will also include a 500l storage tank for storing purified water and 20,000l process water capacity. The purification is based on reverse osmosis and will utilize an automated loop sanitation cycle.
The plant will be equipped with an air compressor, 1,500-gallon nitrogen supply tank, chiller, gas-fired steam boiler, fire sprinkler system, and hot water boiler.
The state-of-the-art equipment and facility is expected to become operational in the second quarter of 2020.
|Morrisville, North Carolina, US
|Scheduled to be operational by 2020